Solriamfetol · Sunosi
Small molecule
Also known as JZP-110
Evidence outlook
Approved: Narcolepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Major Depressive Disorder · Phase 3 · investigational in the USAttention Deficit Hyperactivity Disorder · Phase 3 · investigational in the US
Also approved (2)
- Excessive daytime sleepiness in adults with narcolepsy and in adults with obstructive sleep apnea
- Improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnoea
Development in Parkinson's Disease stopped for reasons the sponsor has not stated. Source
Company guidance: topline data expected 1H 2027 (NCT07484217; Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗
Company guidance: topline data expected 2H 2027 (Axsome Therapeutics, 2 Nov 2026). “Solriamfetol for the treatment of shift work disorder Key eligibility criteria 18-65 years of age with diagnosis of SWD (ICSD-2 or ICSD-3) Primary endpoint Change from baseline in MWT Placebo Solriamfetol (150 mg) Screening (1-4 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R N=450 Follow-up (1 week) SUSTAIN Phase 3 trial Topline results anticipated 2H 2027 MWT = Maintenance of Wakefulness Test 36” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02348593 NCT02348593 · Narcolepsy TONES 2 (Study 1 in the SUNOSI label) was a 12-week, randomized, double-blind, placebo-controlled Phase 3 trial in 239 adults with narcolepsy, testing solriamfetol 75, 150 and 300 mg. The coprimaries were the change in Maintenance of Wakefulness Test sleep latency and in Epworth Sleepiness Scale score. The 150 and 300 mg doses were significant on both (all p<0.0001), but the 75 mg dose was not significant on either. With two doses positive and one not, the result is mixed. Sources: the FDA label (SUNOSI) and Thorpy et al., Ann Neurol 2019. Registry: NCT02348593 | 3 | Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12; Change in ESS Score From Baseline to Week 12 2017-02 | Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | Partial signal | link ↗ |
View 2 more trials
NCT02348632 NCT02348632 · Narcolepsy Study 4 in the SUNOSI label enrolled 638 adults with narcolepsy or obstructive sleep apnea who had completed an earlier solriamfetol trial and gave all of them the drug open-label. After about six months on a stable dose, 282 participants entered a 2-week randomized withdrawal, in which half continued solriamfetol and half switched to placebo. The single primary endpoint was the change in Epworth Sleepiness Scale score over that period. Sleepiness worsened much more after the switch to placebo (+5.3 vs +1.6 points; difference -3.7, 95% CI -4.8 to -2.7), so the primary endpoint was met. Sources: the FDA label (SUNOSI) and the CT.gov posted results. Registry: NCT02348632 | 3 | Change in Epworth Sleepiness Scale (ESS) Score (Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)) 2017-12 | Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). | Partial signal | link ↗ |
OSA NCT02348619 · Obstructive Sleep Apnea Registry: NCT02348619 | 3 | Change in the Maintenance of Wakefulness Test (MWT) (Week 4 to Week 6); Change in the Epworth Sleepiness Scale (ESS) (Week 4 to Week 6) 2016-11 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Dopamine/norepinephrine transporter drugs
Dextromethorphan/bupropion, naltrexone/bupropion. Compare all 3 Dopamine/norepinephrine transporter drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Solriamfetol (Sunosi): this drug | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| Centanafadine (Simtriyo) | Approved | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | |
| Naltrexone / Bupropion (Contrave) | Approved(overall) | Small molecule | Opioid receptor / dopamine (combination), Dopamine/norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Viloxazine (Qelbree) | Approved | Small molecule | norepinephrine transporter | Reliable signal | NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | |
| Lysergide Tartrate (LSD) (DT120) | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sunosi (Solriamfetol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (2)
2028 (3)
June 2028 (2)
December 2028 (1)
Company guidance: topline data expected 1H 2027 (Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent